Sang-We Kim

10.9k total citations · 4 hit papers
47 papers, 5.2k citations indexed

About

Sang-We Kim is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Sang-We Kim has authored 47 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pulmonary and Respiratory Medicine, 37 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Sang-We Kim's work include Lung Cancer Treatments and Mutations (37 papers), Lung Cancer Research Studies (20 papers) and Colorectal Cancer Treatments and Studies (11 papers). Sang-We Kim is often cited by papers focused on Lung Cancer Treatments and Mutations (37 papers), Lung Cancer Research Studies (20 papers) and Colorectal Cancer Treatments and Studies (11 papers). Sang-We Kim collaborates with scholars based in South Korea, Taiwan and United States. Sang-We Kim's co-authors include James Chih‐Hsin Yang, Myung‐Ju Ahn, Wu‐Chou Su, Dong‐Wan Kim, Enriqueta Felip, Leora Horn, Mireille Cantarini, Paul Frewer, Joo-Hang Kim and Keunchil Park and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

Sang-We Kim

46 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

2015 1.6k citations James Chih‐Hsin Yang, Dong‐Wan Kim et al. profile →
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

2012 776 citations Vincent A. Miller, Vera Hirsh et al. The Lancet Oncology profile →
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

2016 397 citations Martin Reck, Alexander Luft et al. Journal of Clinical Oncology profile →
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

2020 295 citations Ji‐Youn Han, Myung‐Ju Ahn et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Sang-We Kim

Since Specialization

Citations

This map shows the geographic impact of Sang-We Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sang-We Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sang-We Kim more than expected).

Fields of papers citing papers by Sang-We Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sang-We Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sang-We Kim. The network helps show where Sang-We Kim may publish in the future.

Co-authorship network of co-authors of Sang-We Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Sang-We Kim. A scholar is included among the top collaborators of Sang-We Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sang-We Kim. Sang-We Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Amivantamab plus capmatinib in advanced non-small cell lung cancer (NSCLC) harboring MET alterations: Recommended phase 2 combination dose and preliminary dose-escalation results from the phase 1/2 METalmark study. 2024 ·Journal of Clinical Oncology ·Alexander I. Spira, Byoung Chul Cho, (unknown), Sang-We Kim, Bing Xia, (unknown), Jessica Dobbs, Christine Baudelet, Mahadi Baig, Mehmet Alı Nahıt Şendur	3
2	Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial 2024 ·BMC Cancer ·Joon Oh Park, Yin‐Hsun Feng, Wu‐Chou Su, Do‐Youn Oh, Bhumsuk Keam, Lin Shen, Sang-We Kim, (unknown), Huimin Liao, Min Qing, Chong Zhang, Jiaqi Qian, (unknown), Liming Peng, Spyros Triantos, Hussein Sweiti	9
3	A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer 2020 ·British Journal of Cancer ·Jin Hyoung Kang, (unknown), Dong‐Wan Kim, Sang-We Kim, Hye Ryun Kim, Joo-Hang Kim, Jin-Hyuk Choi, Ho Jung An, Jin-Soo Kim, Joung-Soon Jang, Bong-Seog Kim, Heung Tae Kim	18
4	Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study 2019 ·The Lancet Respiratory Medicine ·Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, Jianying Zhou, Yiping Zhang, Jianxing He, Jin-Ji Yang, Ying Cheng, Se‐Hoon Lee, Lilian Bu, Tingting Xu, Li Yang, Chao Wang, Ting Liu, Peter N. Morcos, You Lu, Li Zhang	186
5	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression 2019 ·Journal of Cancer Research and Clinical Oncology ·Martin Schüler, Eng-Huat Tan, Kenneth J. O’Byrne, Li Zhang, Michael Boyer, Tony Mok, Vera Hirsh, James Chih‐Hsin Yang, Ki Hyeong Lee, Shun Lü, Yuankai Shi, Sang-We Kim, Janessa Laskin, Dong‐Wan Kim, Catherine Dubos Arvis, Karl Kölbeck, Dan Massey, Angela Märten, Luis Paz‐Ares, Keunchil Park	31
6	Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol 2019 ·Clinical Lung Cancer ·Benjamin Levy, Luis Paz‐Ares, Jaafar Bennouna, Enriqueta Felip, Delvys Rodríguez‐Abreu, Dolores Isla, Fabrice Barlési, Olivier Molinier, J. Madelaine, Clarisse Audigier-Valette, Sang-We Kim, Hye Ryun Kim, Mustafa Özgüroğlu, Mustafa Erman, Firas Badin, Tarek Mekhail, Ronald Scheff, Michael Chisamore, (unknown), Jonathan W. Riess	8
7	Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea 2018 ·Lung Cancer ·Moon Ki Choi, Jin Seok Ahn, Young‐Chul Kim, Byoung Chul Cho, In‐Jae Oh, Sang-We Kim, Jong Seok Lee, Joo-Hang Kim, Myung‐Ju Ahn, Keunchil Park	6
8	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy 2018 ·Lung Cancer ·Jong Seok Lee, Ki Hyeong Lee, Eun Kyung Cho, Dong‐Wan Kim, Sang-We Kim, Joo-Hang Kim, Byoung Chul Cho, Jin Hyoung Kang, Ji‐Youn Han, Young Joo Min, Keunchil Park	24
9	ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC) 2017 ·Journal of Thoracic Oncology ·Byoung Chul Cho, Dong‐Wan Kim, Alessandra Bearz, Scott A. Laurie, Mark J. McKeage, Gloria Borra, Keunchil Park, Sang-We Kim, Marwan Ghosn, Andrea Ardizzoni, Evaristo Maiello, Alastair Greystoke, Richard Yu, Karen A. Osborne, Wen Gu, Jeffrey W. Scott, Vanessa Q. Passos, Yvonne Lau, Anna Wrona	126
10	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study 2017 ·The Lancet Respiratory Medicine ·Myung‐Ju Ahn, Dong‐Wan Kim, Byoung Chul Cho, Sang-We Kim, Jong Seok Lee, Jin-Seok Ahn, Tae Min Kim, Chia‐Chi Lin, Hye Ryun Kim, Thomas John, Steven Kao, Jonathan W. Goldman, Wu‐Chou Su, Ronald B. Natale, (unknown), (unknown), Philip Overend, Zhenfan Yang, James Chih‐Hsin Yang	86
11	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer breakdown → 2016 ·Journal of Clinical Oncology ·Martin Reck, Alexander Luft, Aleksandra Szczęsna, Libor Havel, Sang-We Kim, Wallace Akerley, M. Catherine Pietanza, Yi‐Long Wu, Christoph Zielinski, Michael J. Thomas, Enriqueta Felip, Kathryn A. Gold, Leora Horn, Joachim G.J.V. Aerts, Kazuhiko Nakagawa, Paul Lorigan, Anne Pieters, (unknown), Justin Fairchild, David R. Spigel	397
12	Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer 2016 ·Investigational New Drugs ·Giorgio V. Scagliotti, Jin Hyoung Kang, David C. Smith, Richard K. Rosenberg, Keunchil Park, Sang-We Kim, Wu‐Chou Su, Thomas E. Boyd, Donald Richards, Silvia Novello, Scott M. Hynes, Scott P. Myrand, Ji Lin, Emily Nash Smyth, Sameera R. Wijayawardana, Aimee Bence Lin, Mary Pinder-Schenck	55
13	Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR 2015 ·BMC Cancer ·Yoon Ji Choi, Dae Ho Lee, Chang‐Min Choi, Jung Shin Lee, Seung Jin Lee, Jin Hee Ahn, Sang-We Kim	15
14	ROS1 Receptor Tyrosine Kinase, a Druggable Target, is Frequently Overexpressed in Non-Small Cell Lung Carcinomas Via Genetic and Epigenetic Mechanisms 2012 ·Annals of Surgical Oncology ·Hee Jin Lee, Hyang Sook Seol, Joo Young Kim, Sung‐Min Chun, Young‐Ah Suh, Young-Soo Park, Sang-We Kim, Chang‐Min Choi, Seung-Il Park, Dong Kwan Kim, Yong‐Hee Kim, Se Jin Jang	44
15	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial breakdown → 2012 ·The Lancet Oncology ·Vincent A. Miller, Vera Hirsh, Jacques Cadranel, Yuh-Min Chen, Keunchil Park, Sang-We Kim, Caicun Zhou, Wu‐Chou Su, Mengzhao Wang, Yan Sun, Dae Seog Heo, Lucio Crinò, Eng-Huat Tan, Tsu-Yi Chao, Mehdi Shahidi, Xiuyu Julie Cong, Robert M. Lorence, James Chih‐Hsin Yang	776
16	FDG-PET as a Potential Tool for Selecting Patients with Advanced Non–Small Cell Lung Cancer Who May Be Spared Maintenance Therapy after First-Line Chemotherapy 2011 ·Clinical Cancer Research ·Dok Hyun Yoon, Sora Baek, Chang‐Min Choi, Dae Ho Lee, Cheolwon Suh, Jin‐Sook Ryu, Dae Hyuk Moon, Jung Shin Lee, Sang-We Kim	13
17	Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach 2011 ·Journal of Thoracic Oncology ·Manuel Salto‐Tellez, Ming‐Sound Tsao, Jin‐Yuan Shih, Sumitra Thongprasert, Shun Lü, Gee‐Chen Chang, Joseph S. K. Au, Teh‐Ying Chou, Jong Seok Lee, (unknown), (unknown), Jin Hyoung Kang, Sang-We Kim, Soo‐Yong Tan, James Chih‐Hsin Yang	33
18	An indirect comparison of bevacizumab plus cisplatin‐gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first‐line non‐squamous non‐small cell lung cancer in East Asia 2011 ·Asia-Pacific Journal of Clinical Oncology ·John Wen-Cheng Chang, Sumitra Thongprasert, (unknown), Kenneth W.T. Tsang, Heung Tae Kim, (unknown), (unknown), Jin Hyoung Kang, Sang-We Kim, Stefan Walzer	5
19	Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis 2009 ·Lung Cancer ·Jeong-Eun Kim, Dae Ho Lee, Yunsuk Choi, Dok Hyun Yoon, Sang-We Kim, Cheolwon Suh, Jung‐Shin Lee	173
20	Phase II Trial of Gemcitabine-Carboplatin-Paclitaxel as Neoadjuvant Chemotherapy for Operable Non-small Cell Lung Cancer 2006 ·Journal of Thoracic Oncology ·Raymond P. Abratt, (unknown), Ji Youn Han, Chun-Ming Tsai, Michael Boyer, Tony Mok, Sang-We Kim, Jin Soo Lee, Alan Brnabic, William H. H. Reece, M. Lehnert	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact